2005
DOI: 10.1007/s00280-005-0152-y View full text |Buy / Rent full text
|
|

Abstract: This schedule allows oxaliplatin and gemcitabine to be delivered at the full dose intensity of each drug with excellent tolerability and predictable pharmacokinetics. The recommended doses for phase II studies are oxaliplatin 70 mg/m(2) and gemcitabine 1,250 mg/m(2) on days 1 and 8 every 21 days.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
1
4
16
0

Year Published

2011
2011
2011
2011

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

4
16
0
Order By: Relevance
“…Ten patients (23%) received six cycles of treatment, with a cumulative exposure to oxaliplatin in excess of 800 mg/m 2 . This confirms the finding of our phase I study of this regimen, 8 where there was negligible neurosensory toxicity in 21 patients despite a median oxaliplatin dose of 520 mg/m 2 .…”
Section: Discussionsupporting
See 4 more Smart Citations
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Ten patients (23%) received six cycles of treatment, with a cumulative exposure to oxaliplatin in excess of 800 mg/m 2 . This confirms the finding of our phase I study of this regimen, 8 where there was negligible neurosensory toxicity in 21 patients despite a median oxaliplatin dose of 520 mg/m 2 .…”
Section: Discussionsupporting
“…8 PK parameters were determined using non-compartmental analysis. In summary, both drugs displayed a linear relationship between dose and AUC.…”
Section: Discussionmentioning
See 3 more Smart Citations